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ABSTRACT
INTRODUCTION: Atrial fibrillation (AF) is one of the main risk factors for stroke. 
Vitamin K antagonists (VKA) reduce this risk, and the effectiveness of this treatment 
is directly related to time in therapeutic range (TTR). This study aimed to report the 
TTR in patients with non-valvular AF at an anticoagulation outpatient clinic; and to 
describe the profile of this population of patients in terms of risk of stroke, as well as 
the occurrence of adverse events during the follow-up.
METHODS: Retrospective cohort study involving patients of the anticoagulation 
outpatient clinic of the Department of Internal Medicine at Hospital de Clínicas de Porto 
Alegre. We evaluated outpatient visits, hospital admissions, and emergency visits 
from January to December 2011. TTR was calculated using the Rosendaal method.
RESULTS: Sixty-three patients were investigated. Their mean age was 
74.3±10.9 years. The CHADS2 score was ≥ 4 in 44.5% of the patients; 63.5% of 
them had a CHA2DS2-VASc score ≥ 5. The TTR was 64.8%. During follow-up, the 
incidence of overall bleeding was 31.7%, with major and minor bleeding rates of 
4.8% and 34.9%, respectively. There were no other complications related to AF or 
anticoagulation.
CONCLUSION: The patients achieved a TTR of 64.8% during follow-up, which is 
deemed appropriate and in agreement with the literature. Patients had high risk for 
stroke, and the incidence of minor bleeding was higher than the rate found in the 
literature, whereas the incidence of major bleeding was similar to the one found in 
previous studies. 
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Atrial fibrillation (AF) is the most common clinically 
significant cardiac arrhythmia. Prevalence of AF is 
approximately 0.4% in the general population and 
may be up to 9% in individuals aged 80 years or 
more1. AF increases the risk of death and of systemic 
and brain thromboembolism, particularly ischemic 
stroke (relative risk of stroke is 2.4 to 3.0 compared 
with the overall population)2,3.
Vitamin K antagonists, such as warfarin and 
phenprocoumon, reduce the risk of ischemic 
stroke in patients with AF by approximately 
60%4. Effectiveness of treatment with vitamin K 
antagonists is directly related to time in optimal 
therapeutic range (percentage time with a 
prothrombin time/international normalized ratio [PT/
INR] of 2.0-3.0)5. In a systematic review, the mean 
time in therapeutic range of randomized trials was 
66.4%, with no statistically significant difference 
when compared to the mean time observed at 
outpatient anticoagulation clinics. This means 
even in large studies, for a significant percentage 
of time, patients do not get optimal benefits from 
these drugs6.
Randomized studies have already shown that 
management of anticoagulation by anticoagulation 
clinics is at least as good as routine hospital 
follow-up7, and marginally better than management 
by family physicians8. These clinics are 
usually managed by specialized professionals 
(hematologists, cardiologists, nurses specialized 
in anticoagulation). The primary objective of the 
present study was to report the time in therapeutic 
range on oral anticoagulant therapy with vitamin K 
antagonists in patients with non-valvular AF at an 
outpatient anticoagulation clinic from a Brazilian 
teaching hospital. The secondary objective of our 
study was to describe the profile of this patient 
population in terms of risk of ischemic stroke, as 
well as the occurrence of adverse events during 
the study period.
METHODS
We conducted a retrospective cohort study 
including patients with non-valvular AF on oral 
anticoagulation with vitamin K antagonists 
attending the outpatient anticoagulation clinic of 
the Department of Internal Medicine at Hospital 
de Clínicas de Porto Alegre (HCPA). This hospital 
is a tertiary care teaching hospital located in 
an upper-middle-class area in southern Brazil. 
However, most patients at the HCPA are from a 
low-income background.
The patients at the outpatient anticoagulation 
clinic of the Department of Internal Medicine at HCPA 
are attended by first year Internal Medicine resident 
physicians. These healthcare professionals are 
supervised by attending physicians, specialized in 
Internal Medicine. The residents are guided during 
work at the clinic and attend a one-hour lecture at 
the beginning of the residence program. The clinic 
receives approximately 40 to 60 patients over 4 
days a week. All decisions regarding management 
of anticoagulation are based on a protocol published 
by Kim et al.9.
All patients who visited the clinic in three 
consecutive months (October to December 
2010) were screened for inclusion in the study. 
We believe that screening this time range was 
adequate, since the patients attended the clinic at 
a maximum interval of two months. Patients with 
valvular AF, i.e., with mitral stenosis or previous 
heart valve surgery, were excluded because the 
ischemic stroke predictive scores (CHADS2 and 
CHA2DS2-VASc) do not include these disorders in 
their analyses10,11. Patients who were lost to follow-
up, who died or whose anticoagulation therapy was 
discontinued were included in our analysis, and the 
time in therapeutic range was measured until the 
last test available. 
We performed a retrospective review 
of outpatient visits, emergency visits, and 
hospitalizations from January to December 2011 
based on the patients’ electronic medical records. 
Patients were evaluated for anticoagulation control 
(using PT/INR tests) and occurrence of adverse 
events (ischemic stroke, systemic embolism, or 
bleeding). 
Presence of chronic dialysis or renal 
transplantation or serum creatinine ≥ 200 μmol/L 
(2.26 mg/dL) was classified as abnormal kidney 
function12. Abnormal liver function was defined 
as chronic hepatic disease (e.g., cirrhosis) or 
biochemical evidence of significant hepatic 
derangement (e.g., bilirubin > 2x upper limit of 
normal, in association with AST/ALT/ALP >3 x 
upper limit of normal)12. Major bleeding was defined 
as any bleeding requiring hospitalization and/or 
causing a decrease in hemoglobin level > 2 g/dL 
and/or requiring blood transfusion12. 
The mean risk of ischemic stroke was calculated 
based on the risk factors included in the CHADS2 
and CHA2DS2-VASc scores. Thus, we assessed 
age, sex, left ventricular ejection fraction (LVEF), 
complex aortic plaque and history of transient 
ischemic attack (TIA), stroke, diabetes, peripheral 
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artery disease, hypertension, myocardial infarction, 
and heart failure. Previous systemic embolism, 
combined use of antiplatelet agents, oral 
anticoagulant (warfarin or phenprocoumon), and 
number of PT/INR tests were also investigated.    
The CHADS2 score was calculated based on 
the presence of cardiac failure, hypertension, 
age above 75 years, diabetes, and prior stroke 
or TIA, as previously described10. The CHA2DS2-
VASc included ages 65-74, female gender and 
vascular disease, and age 75 and above also 
carries extra weight, with 2 points11. LVEF was 
obtained from the transthoracic echocardiogram, 
measured by the Simpson method in the 
presence of segmental changes or by the Teicholz 
method in the absence of segmental changes. 
Determination of the INR through prothrombin time 
was performed at the Haematology Laboratory 
of Hospital de Clínicas de Porto Alegre using a 
standard coagulometric method (Siemens BCS).
Time in therapeutic range was calculated 
based on the percentage of PT/INR tests in 2.0-
3.0 range and Rosendaal’s linear interpolation 
method13, using the INR-Day 0.2.1 software. This 
method assumes that the PT/INR value between 
two measurements will vary linearly from the 
value of the first measurement to the value of 
the second measurement (Figure 1A). Therefore, the 
time between two measurements is divided into 
days, and small intervals of PT/INR are used 
over the range of the time interval. Subsequently, 
the person-time at each PT/INR value is added 
up over all measurements of all patients and 
then grouped into 0.5 PT/INR cells (Figure 1B). 
Descriptive data were reported as number (%) 
and mean ± standard deviation (SD). We used 
SPSS 15.0 for statistical analysis. 
Using a 95% confidence level and a margin 
of error of 3.5, we calculated a sample size of 
53 patients in order to estimate the stroke and/or 
systemic embolization outcomes (annual incidence 
1.69%14), and 47 patients for major bleeding (annual 
incidence 1.5%12). For the minor bleeding outcome, 
the calculated sample was 47 patients, using a 
margin of error of 8% and a 95% confidence level 
(annual incidence of 9.615). We used the WinPepi 
11.32 software for this analysis.
This study was approved by the Research 
Ethics Committee of the Hospital de Clínicas 
de Porto Alegre.All authors complied with the 
recommendations of the Declaration of Helsinki.
RESULTS
During the study period, 137 patients were 
attended at the outpatient anticoagulation 
clinic of the Department of Internal Medicine at 
HCPA. Out of these, 63 (46.0%) were receiving 
anticoagulation treatment for non-valvular 
AF and were included in the study. During the 
follow-up period, 8 patients did not complete the 
one-year follow-up: 5 discontinued the use of 
anticoagulants (7.9%), 2 were lost to follow-up 
(3.2%), and 1 died (1.6%) of a cause unrelated to 
anticoagulation. Thus, of the 63 patients included 
in the study, 55 completed the 365-day follow-up 
period (Figure 2), and the other 8 patients had a 
mean follow-up of 128.5 days. The demographic 
characteristics of the sample are shown in 
Table 1. There were no patients with abnormal 
kidney or liver function. The presence of complex 
aortic plaques was not included in Table 1 
because only 4 patients (6.3%) underwent 
transesophageal echocardiogram.
Figure 1: Rosendaal’s linear interpolation method13.
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had a CHA2DS2-VASc score ≥ 5 (median of 5 points). 
Since patients with a score ≥ 2 are considered to be 
at high risk, with an indication for anticoagulation 
according to the CHADS2 and CHA2DS2-VASC 
scores, 95.2% and 100% of our patients, respectively, 
were included in this risk category.
During the follow-up period, 20 (31.7%) patients 
experienced at least one adverse event. As shown 
in Table 2, only bleeding was described, and no 
patient presented a thromboembolic event. 
DISCUSSION
In the present study, we showed that patients 
followed up at our anticoagulation clinic have a 
time in therapeutic range of 64.8%. Moreover, this 
group of patients is at high risk for ischemic stroke 
(demonstrated by high scores on the CHADS2 
and CHA2DS2-VASc scores). The incidence of 
minor bleeding is higher than the one found in the 
literature, whereas the incidence of major bleeding 
was similar to the one described in previous studies.
Table 1: Demographic characteristics of the sample.
Characteristics n = 63
Age, years 74.3 ± 10.9
Age ≥ 75 years 39 (61.9)
Female gender 31 (49.2)
Use of warfarin 62 (98.4)
Hypertension 62 (98.4)
Heart failure 42 (66.7)
LVEF (%) 56.1 ± 12.3
LVEF < 40% 7 (11.1)
Diabetes 32 (50.8)
Associated use of ASA 21 (33.3)
Prior stroke 20 (31.7)
Previous AMI 10 (15.9)
Peripheral arterial disease 10 (15.9)
Previous systemic embolism 4 (6.3)
Previous TIA 1 (1.6)
Data presented as number (%), mean ± standard-deviation. LVEF: left 
ventricular ejection fraction, ASA: acetylsalicylic acid, AMI: acute 
myocardial infarction, TIA: transient ischemic attack.
Table 2: Adverse events during follow-up.
Adverse event* n (%)
Major bleeding 3 (4.8)
     Severe anemia**     1 (1.6)
     Skin bruise 1 (1.6)
     Hemothorax caused by fall 1 (1.6)
Minor bleeding 22 (34.9)
     Genitourinary 7 (11.1)
     Cutaneous 4 (6.3)
     Epistaxis 4 (6.3)
     Bleeding gums 3 (4.8)
     Gastrointestinal 2 (3.2)
     Hemoptysis 2 (3.2)
*Some patients had more than one type of bleeding; **Hb 5.8 g/L, 
requiring blood transfusion and hospitalization without exteriorization.  
137 patients
63 non-valvular AF patients
55 patients with complete follow-up
74 (54.0%) patients excluded
26 (19.0%) isolated DVT
21 (15.3%) PE
14 (10.2%) metal prosthesis
  8 (5.8%) valvular AF
  5 (3.7%) other reasons
8 (12.7%) without complete follow-up
5 (7.9%) use discontinued
2 (3.2%) loss to follow-up
1 (1.6%) death
Figure 2: Enrollment and follow-up.
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Figure 3: Time in therapeutic range.
The 63 patients included in the present study 
underwent 738 PT/INR tests (mean 11.7±5.1 tests/
patient). Of these, 395 tests (53.5%) showed INR 
between 2.0 and 3.0. As for time in therapeutic 
range, analyzed by Rosendaal’s linear interpolation 
method, PT/INR remained between 2.0 and 2.9 in 
64.8% of the follow-up period; and was between 
1.5 and 3.4 in 89.9% of the follow-up period. The 
distribution of PT/INR ranges by follow-up days is 
presented in Figure 3.
Regarding risk of stroke, we found that our patients 
were at high risk for this outcome: 44.5% of them had 
a CHADS2 score ≥ 4 (median of 3 points), and 63.5% 
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The percentage of time in therapeutic range 
is strongly associated with risk of bleeding and 
occurrence of thromboembolic events in patients 
receiving oral anticoagulant therapy with vitamin 
K antagonists6. Wallentim et al.16 divided the 
time in therapeutic range of 5,791 patients with 
AF on warfarin into quartiles (< 53.6, 53.6-67.2, 
67.2-78.4, and > 78.4%) and found a significant 
inverse association between the quartiles and 
the rate of stroke/systemic embolism (2.34, 1.72, 
1.42, and 1.25%; p = 0.001), major bleeding 
(4.95, 3.71, 2.98, and 2.65%; p < 0.0001), 
total mortality (7.48, 3.30, 2.27, and 2.65%; 
p < 0.0001), and composite outcome of stroke, 
systemic embolism, pulmonary embolism, major 
bleeding and death (12.32, 7.35, 5.55, and 5.4%; 
p < 0.0001).
Walraven et al.6, in a systematic review of the 
literature, analyzed anticoagulated patients from 
anticoagulation clinics and described a mean 
time in therapeutic range of 65.6% (95%CI 63.7-
67.6%), without a significant difference when 
compared to the patients included in randomized 
clinical trials. It is worth mentioning that, even 
in recent large randomized clinical trials, using 
strict protocols, the percentage found is not really 
very different, and it may be even lower: the 
mean of the ROCKET AF study was 55%17, 
the mean of the RE-LY study was 64%14, and the 
mean of the ARISTOTLE study was 66%18. 
Connolly et al.19 suggested that there is a target 
time in therapeutic range, which is estimated 
between 58-65%. This target has been suggested 
as the cutoff for patients to actually derive benefit 
from oral anticoagulants when compared to 
the use of dual antiplatelet therapy. This study 
showed that patients with TTR < 58-65% had 
similar adverse event rates when compared to 
subjects treated with acetylsalicylic acid (ASA) 
plus clopidogrel. Notably, the mean overall TTR 
for Brazilian sites in this study was 47.1% and 
64.8% in this report. This highlights the potential 
benefit of using our clinic model/protocol in the 
context of the public health care system. 
Pisters et al.12, in a large recent study including 
3,456 ambulatory and hospitalized AF patients 
from teaching, non-teaching, and specialized 
hospitals in European countries, using the same 
definitions of major bleeding used in this analysis, 
described an annual incidence of major bleeding 
of 1.5%. In a previous meta-analysis, the mean 
annual frequency of major/minor bleeding with 
use of anticoagulants was 3.0% and 9.6%, 
respectively15. Thus, the rate of major bleeding 
found in the present study (4.8%) is similar to 
that described in the literature, whereas the rate 
of minor bleeding (34.9%) was higher. Possible 
explanations for this discrepancy include: small 
sample size, different definitions of bleeding 
used in different studies, and possible increased 
predisposition to bleeding in our sample due to a 
high prevalence of elderly patients and patients 
with multiple comorbidities.
There are some limitations in our study. First, 
the retrospective design may have influenced 
the quality and consistency of the data collected. 
Besides, the chart review of the patients could 
only identify events (cardiovascular and bleeding) 
that occurred at HCPA or that were reported by 
the patients in clinical care. Second, the relative 
small sample size associated with the short 
follow-up period may have underestimated the 
occurrence of adverse events, especially events 
related to AF, which have a longer latency period. 
Finally, the fact that the study was conducted at a 
single center can also be considered a limitation. 
The patients with non-valvular AF on oral 
anticoagulant therapy managed at an outpatient 
clinic at a teaching hospital achieve an optimal 
time in therapeutic range of 64.8% during the 
12-month follow-up period, which is deemed 
appropriate and in agreement with the literature. 
These data are important because they show 
that this strategy is a feasible approach for 
patients treated within the context of the 
Brazilian public health system at a teaching 
hospital and could expand the coverage for 
patients who need this therapy. 
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